The relationship between the timing of tumor sample collection used for assessment of HER2 IHC/ISH status and patient outcomes revealed that clinically meaningful ORR was observed regardless of the timing of sample collection in our study (that is, before or after/during the first Tmab treatment). The gene discussed is ERBB2; the disease is neoplasm.